Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathyTelitacicept Shows Favorable Safety Profile for IgA Nephropathy

Frontiers in Medicine Published August 5, 2026 Study authors: Li Zheng, Xiaotong Gu, Chumeng Yang, Weina Zhang, Changhai Fu, Yan Wang, Xiaoyong Fang DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that telitacicept monotherapy is associated with a lower incidence of adverse drug reactions in IgA nephropathy.

This meta-analysis of observational studies evaluated the efficacy and safety of telitacicept monotherapy and combination therapy in patients with biopsy-confirmed IgA nephropathy. The analysis included data from 459 patients to assess primary outcomes such as complete remission (CR) and secondary outcomes including 24-h urinary protein, estimated glomerular filtration rate, serum creatinine, and albumin.

The authors synthesized findings indicating no statistically significant differences between telitacicept and other immunosuppressive treatments across all efficacy measures. However, a significant safety benefit was identified: telitacicept monotherapy showed a significantly lower incidence of adverse drug reactions compared to control treatments (OR 0.37; 95% CI 0.20-0.67).

The authors noted that evidence certainty ranged from moderate to very low across all outcomes. Furthermore, the lack of statistically confirmed superiority in efficacy outcomes limits current conclusions regarding its comparative effectiveness. Despite these limitations, telitacicept is described as a well-tolerated therapeutic option for IgA nephropathy.

How this fits prior evidence

This meta-analysis addresses a gap in the safety profile of telitacicept for IgA nephropathy. It complements prior evidence showing that telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trials, while this analysis focuses on observational data and highlights its favorable tolerability (OR 0.37) compared to other immunosuppressive treatments.

Researchers analyzed data from 459 patients with biopsy-confirmed IgA nephropathy to compare the drug telitacicept against other immunosuppressive treatments. The study looked at several key markers of kidney health, including protein levels in urine, kidney filtration rates, and serum creatinine.

The results showed no statistically significant differences between telitacicept and other treatments regarding primary outcomes like complete remission or secondary measures like albumin levels. While the drug did not show superior effectiveness over current options, it did show a significantly lower incidence of adverse drug reactions compared to control treatments.

Because this analysis was based on observational studies, the evidence for its effectiveness is considered moderate to very low. While telitacicept is described as a well-tolered option with a favorable safety profile, these results do not prove it is more effective than other medications. Patients should discuss these findings with their doctor to determine the best treatment plan.

What this means for you:

Telitacicept shows fewer side effects than some treatments for IgA nephropathy but does not show superior effectiveness.

Common questions

Is telitacicept safe for people with IgA nephropathy?

The study describes telitacicept as a well-tolerated therapeutic option. Patients taking the monotherapy showed a significantly lower incidence of adverse drug reactions compared to those on other treatments (OR 0.37). However, because this was based on observational data, you should talk to your doctor about its safety for your specific case.

Is telitacicept more effective than other treatments?

The study did not find statistically significant differences in effectiveness when comparing telitacicept to other immunosuppressive treatments. Outcomes such as complete remission, urinary protein levels, and kidney filtration rates were similar across the groups studied.

What are the limitations of this research?

The evidence for these findings is considered moderate to very low because the data came from observational studies. While telitacicept has a favorable safety profile, the study did not confirm that it is more effective than other current treatments.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedAug 2026

View Original Abstract ↓

Telitacicept, a dual BAFF/APRIL inhibitor, is a potential targeted therapy for IgA nephropathy (IgAN), but its real-world efficacy and safety remain unclear. We systematically searched PubMed, Embase, Cochrane Central, ClinicalTrials.gov, CNKI, Wanfang, VIP, and SinoMed from inception to 2 March 2026 for observational studies of telitacicept in biopsy-confirmed IgAN. Eligible studies compared telitacicept monotherapy or telitacicept-based combination therapy with other immunosuppressive treatments. Outcomes included complete remission (CR), changes in 24-h urinary protein (Δ24hUPQ), estimated glomerular filtration rate (ΔeGFR), serum creatinine (ΔScr), albumin (ΔAlb), and adverse drug reactions (ADRs). Odds ratios (ORs) and mean differences (MDs) were pooled. Eight observational studies involving 459 patients were included. Compared with other immunosuppressive therapies, telitacicept monotherapy showed no statistically significant differences in CR, Δ24hUPQ, ΔeGFR, ΔScr, and ΔAlb. Similarly, telitacicept-based combination therapy did not show statistically significant differences in CR, Δ24hUPQ, ΔeGFR, ΔScr, and ΔAlb. In terms of safety, telitacicept monotherapy was associated with a significantly lower incidence of ADRs than control treatments (OR 0.37, 95% CI 0.20–0.67). The certainty of evidence ranged from moderate to very low across outcomes. Current observational evidence suggests that telitacicept has a favorable safety profile and may offer clinical benefit in IgAN, particularly as a well-tolerated therapeutic option. Although superiority in efficacy outcomes was not statistically confirmed, the overall direction of effect tended to favor telitacicept in several analyses. Larger high-quality prospective studies are needed to further clarify its therapeutic value. The study was registered in the PROSPERO database (CRD420261296245), https://www.crd.york.ac.uk/PROSPERO/recorddashboard.

Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathyTelitacicept Shows Favorable Safety Profile for IgA Nephropathy

How this fits prior evidence

Common questions

Study Details

Finerenone Efficacy and Safety in Patients with Chronic Kidney Disease and Glomerular Disease

Finerenone slows kidney function loss in patients with glomerular disease

Clinical research that matters. Delivered to your inbox.

Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathyTelitacicept Shows Favorable Safety Profile for IgA Nephropathy

How this fits prior evidence

Common questions

More on IgA Nephropathy

Study Details

Finerenone Efficacy and Safety in Patients with Chronic Kidney Disease and Glomerular Disease

Finerenone slows kidney function loss in patients with glomerular disease

Clinical research that matters. Delivered to your inbox.

Related in Nephrology

From Other Specialties